Waters Corp (WAT) Stock
NASDAQ · WAT
436.45
Fundamentals
Market cap
$42.59B
Price / Earnings ratio
254.5x
Price / Sales ratio
9.1x
Price / Book ratio
2.8x
Return on assets
5.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
NeutralWATSeptember 26, 2026
MarketBeatNeutral
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
WAT

Zacks Investment Research
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
NeutralWATSeptember 18, 2026
Zacks Investment ResearchNeutral
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT

Business Wire
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
NeutralWATSeptember 16, 2026
Business WireNeutral
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WAT

Zacks Investment Research
Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
NeutralWATSeptember 3, 2026
Zacks Investment ResearchNeutral
Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
WAT
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral2
Buy10
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
4B3B1B0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
6B4B2B0
Revenue to Profit
2025$3.2B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$642.6M
Net incomeEarnings
EPS forecast
Actual EPS
$2.95
$2.94
Q2FY25
$3.40
$3.21
Q3FY25
$4.51
Q4FY25
$2.51
Q1FY26
$3.29
Q2FY26
The market is expecting earnings per share of $3.29 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
NeutralWATSeptember 26, 2026
MarketBeatNeutral
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
WAT

Zacks Investment Research
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
NeutralWATSeptember 18, 2026
Zacks Investment ResearchNeutral
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT

Business Wire
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
NeutralWATSeptember 16, 2026
Business WireNeutral
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WAT

Zacks Investment Research
Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
NeutralWATSeptember 3, 2026
Zacks Investment ResearchNeutral
Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
WAT

Business Wire
LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
NeutralWATAugust 27, 2026
Business WireNeutral
LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WAT

MarketBeat
Waters Q2 Earnings Call Highlights
NeutralWATAugust 9, 2026
MarketBeatNeutral
Waters Q2 Earnings Call Highlights
WAT

Zacks Investment Research
Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised
NeutralWATAugust 5, 2026
Zacks Investment ResearchNeutral
Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised
WAT

Zacks Investment Research
Waters (WAT) Q2 Earnings and Revenues Beat Estimates
NeutralWATAugust 4, 2026
Zacks Investment ResearchNeutral
Waters (WAT) Q2 Earnings and Revenues Beat Estimates
WAT

Zacks Investment Research
Waters (WAT) Earnings Expected to Grow: Should You Buy?
NeutralWATJuly 28, 2026
Zacks Investment ResearchNeutral
Waters (WAT) Earnings Expected to Grow: Should You Buy?
WAT

Zacks Investment Research
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
NeutralWATJuly 27, 2026
Zacks Investment ResearchNeutral
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
WAT
About Waters Corp
Waters is the world's leading specialty measurement company focused on improving human health and well-being through the application of high-value analytical technologies and industry leading scientific expertise. Waters has continually pioneered chromatography, mass spectrometry and thermal analysis innovations.
SectorHealthcare
IndustryDiagnostics & Research
Employees16,000
CEODr. Udit Batra Ph.D.
IPO DateNov 16, 1995
HeadquartersMilford, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Udit Batra Ph.D. | President, CEO & Director | 1971 |
| Mr. Amol Chaubal | Senior VP & CFO | 1977 |
| Ms. Jianqing Y. Bennett | Senior Vice President of Waters Advanced Diagnostics Division | 1970 |
| Mr. Christos Ross | Senior Vice President of Global Operations | — |
| Mr. Brook M. Colangelo | Senior VP & Chief Information Officer | 1978 |
| Mr. Caspar Tudor | Head of Investor Relations | — |
| Ms. Keeley A. Aleman J.D. | Senior VP, General Counsel, Head of Global Human Resources & Corporate Secretary | 1977 |
| Ms. Kristen Garvey | Senior Vice President of Global Communications | — |
| Dr. Daniel Rush Ph.D. | Senior Vice President of Global Research & Strategy | — |
| Mr. Allan Jaenicke | Senior Vice President of Transformation | — |
Fundamentals
Valuation
Market cap$42.59B
Price-to-sales ratio9.10
Price-to-book value2.78
Price-earnings ratio254.50
Return on Equity8.00%
Return on Sales17.00%
Return on Assets5.00%
PEG ratio1.60
Earnings Per Share
Earnings Per Share$4.03
Income Statement
Average volume648,797
EBITDA$991.44M
1 year high (52w)$436.34
1 year low (52w)$282.77
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
12 Wall Street Analyst Ratings
BUY
83% Buy
17% Hold
0% Sell
Target price
$453.33
Est return
3.82%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.2 | +3.3 | -10.0 | +13.4 | ||||||||
| 2022 | -12.2 | -2.2 | -1.0 | -1.8 | +8.5 | +2.9 | +8.1 | -18.3 | -10.3 | +7.9 | +12.7 | -1.3 |
| 2023 | -4.9 | -8.0 | +0.1 | -2.3 | -15.8 | +4.1 | +4.3 | +2.3 | -2.4 | -11.8 | +16.5 | +14.0 |
| 2024 | -3.3 | +4.0 | -0.5 | -10.3 | -2.2 | -6.4 | +19.0 | -1.8 | +5.9 | -9.8 | -0.6 | -4.2 |
| 2025 | +12.8 | -8.2 | -0.9 | -2.3 | +2.2 | +1.6 | -19.1 | +4.0 | +1.1 | +9.3 | +16.7 | -4.5 |
| 2026 | -2.9 | -15.8 | -3.1 | +3.1 | +24.9 | -0.8 | -0.2 | +10.6 | +6.8 |



